DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Megan Lam, Michael G. DeGroote School of Medicine, McMaster University, Ontario, Canada. DermNet NZ Editor in Chief: Adjunct A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy edited by Gus Mitchell. August 2020
Dermatomyositis is an autoimmune connective tissue disorder involving the skin and the skeletal muscles. Rarely, dermatomyositis may be caused by medications.
Drug-induced dermatomyositis is also known as drug-induced dermopathy, pseudodermatomyositis, and dermatomyositis-like eruption.
Drug-induced dermatomyositis can affect individuals of any race, age, or sex. Drug-induced dermatomyositis is equally common in males and females. There are very few case reports of drug-induced juvenile dermatomyositis.
The most common cause of drug-induced dermatomyositis is hydroxyurea, associated with 50% of cases reported in the medical literature, and affecting up to 4% of patients taking hydroxyurea. Hydroxyurea has been typically been prescribed for 4-5 years for chronic myeloproliferative disorders.
Many other drugs have been reported to trigger drug-induced dermatomyositis. The list includes the following among many others:
Drug-induced dermatomyositis can present with:
The classic cutaneous findings of dermatomyositis include:
The majority of cases of drug-induced dermatomyositis present with the pathognomonic heliotrope rash and/or Gottron papules of dermatomyositis, with the remainder having skin changes consistent with dermatomyositis, such as nailfold telangiectasia or photosensitive poikiloderma.
Hydroxyurea-induced dermatomyositis typically presents after longterm treatment (2-10 years) with hydroxyurea with skin changes over the backs of the fingers, hands, and periorbital areas of the face. Often other skin side effects of hydroxyurea are also present. Myositis rarely, if ever, occurs.
In contrast, where drug-induced dermatomyositis is not associated with hydroxyurea symptoms and signs develop soon after starting the offending drug (< 2months), and the majority have myositis as well as skin signs.
Dermatomyositis can be associated with adenocarcinoma, a finding not seen in drug-induced dermatomyositis. The majority of malignancies found in patients with drug-induced dermatomyositis are pre-existing haematological disorders, and for most are the reason for the use of the implicated drug.
It may be difficult to distinguish classic dermatomyositis and dermatomyositis induced by drugs. A history of longterm hydroxyurea use or the recent commencement of a new drug should raise the possibility of a drug cause. Confirmation is obtained when the clinical symptoms and signs improve following cessation of the implicated drug.
Serology is usually negative for ANA, anti-Ro, and anti-Jo-1 antibodies. Muscle and skin biopsies shows the same changes as seen in dermatomyositis so cannot be used as distinguishing features.
Skin biopsy shows an interface dermatitis with vacuolar basal cell change, dyskeratotic keratinocytes, and hyper- or hypo-granuloasis.
The differential diagnosis for drug-induced dermatomyositis includes:
These differential diagnoses present with symptoms suggestive of myositis but lack the cutaneous findings of dermatomyositis-like eruption.
Cessation of the implicated drug is usually required, although it may be continued if symptoms and signs are mild. In most cases symptoms will improve following discontinuation of the drug. If dermatomyositis remains active for more than one month after the drug ceased, topical or systemic corticosteroids and/or anti-rheumatic drugs may be added if required.
Physical therapy and activity to maintain muscle and joint mobility are also important.
After stopping the drug, patients with drug-induced dermatomyositis generally experience improvement. Complete resolution of the skin signs has been documented in half the patients, usually within the first two months after drug cessation. By 12 months, the majority had cleared. Numbers and time course were similar for resolution or improvement of the myositis.
Clinical features of hydroxyurea-induced dermatomyositis may resolve quickly within days, or can take years to settle after ceasing the drug. Skin atrophy may persist.
Books about skin diseases
© 2021 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.